Literature DB >> 22244665

Current management of gestational trophoblastic neoplasia.

Donald Peter Goldstein1, Ross S Berkowitz.   

Abstract

Gestational trophoblastic neoplasms are malignant lesions that arise from placental villous and extravillous trophoblast. Four clinicopathologic conditions make up this entity: invasive mole (IM), choriocarcinoma (CCA), placental-site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT). IM and CCA, which make up the majority of these tumors, are highly responsive to chemotherapy with an overall cure rate exceeding 90%, making it usually possible to achieve cure while preserving reproductive function. PSTT and ETT, which rarely occur, are relatively resistant to chemotherapy, making surgery the primary treatment modality, chemotherapy being used only when the disease has metastasized.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22244665     DOI: 10.1016/j.hoc.2011.10.007

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  25 in total

1.  Effectiveness and Safety of Toripalimab Combination Therapies for Patients With Chemo-Resistant Choriocarcinoma.

Authors:  Xiaomei Liu; Xiuqin Li; Hui Qu; Shiyue Zhang; Ruizhe Zhang; Zhenhua Du
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

Review 2.  Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia.

Authors:  Qiuyi Wang; Jing Fu; Lina Hu; Fang Fang; Lingxia Xie; Hengxi Chen; Fan He; Taixiang Wu; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2017-09-11

Review 3.  Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia.

Authors:  Mo'iad Alazzam; John Tidy; Raymond Osborne; Robert Coleman; Barry W Hancock; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2016-01-13

4.  Whole brain radiotherapy for brain metastasis.

Authors:  Emory McTyre; Jacob Scott; Prakash Chinnaiyan
Journal:  Surg Neurol Int       Date:  2013-05-02

5.  Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death.

Authors:  Ana Domostegui; Suresh Peddigari; Carol A Mercer; Flavia Iannizzotto; Marta L Rodriguez; Marta Garcia-Cajide; Virginia Amador; Sarah T Diepstraten; Gemma L Kelly; Ramón Salazar; Sara C Kozma; Eric P Kusnadi; Jian Kang; Antonio Gentilella; Richard B Pearson; George Thomas; Joffrey Pelletier
Journal:  Blood       Date:  2021-06-17       Impact factor: 25.476

6.  A rare case of gestational trophoblastic neoplasia following an ectopic molar pregnancy.

Authors:  Sarah Dollinger; Effi Yeoshoua; Ram Eitan
Journal:  Gynecol Oncol Rep       Date:  2021-05-30

7.  Clinical assessment of prophylactic chemotherapy in treating with hydatidiform mole: A protocol for systematic review and meta-analysis.

Authors:  Feng Xu; Yan-Li Zheng; Xiao-Yan Lu; Hai-Feng Qiao; Ying Wang
Journal:  Medicine (Baltimore)       Date:  2021-06-18       Impact factor: 1.817

8.  NLRP7 and the Genetics of Hydatidiform Moles: Recent Advances and New Challenges.

Authors:  Rima Slim; Evan P Wallace
Journal:  Front Immunol       Date:  2013-08-20       Impact factor: 7.561

9.  Clinical Outcome of a FIGO Stage IV Gestational Choriocarcinoma.

Authors:  Vera Milenković; Biljana Lazović; Marija Mačvanski; Katarina Jeremić; Zlatko Hrgović
Journal:  Case Rep Oncol       Date:  2013-09-28

10.  Tegafur Substitution for 5-Fu in Combination with Actinomycin D to Treat Gestational Trophoblastic Neoplasm.

Authors:  Mei Peng; Yiling Ding; Ling Yu; Yali Deng; Weisi Lai; Yun Hu; Hongwen Zhang; Xianqing Wu; Hong Fan; Hui Ding; Yilin Wu; Guangshi Tao
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.